Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Yue, Tingting ^a,f   Maupin, Kevin A ^a   Fallon, Brian ^a   Li, Lin ^b   Partyka, Katie ^a   Anderson, Michelle A ^c   Brenner, Dean E ^c   Kaul, Karen ^d   Zeh, Herbert ^e   Moser, A James ^e   Simeone, Diane M ^c   Feng, Ziding ^b   Brand, Randall E ^e   Haab, Brian B ^a  

^a VAN ANDEL INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; MUCIN; MUCIN 16; MUCIN 5AC; UNCLASSIFIED DRUG; CA 125 ANTIGEN; CARRIER PROTEIN; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; MUC5AC PROTEIN, HUMAN; TUMOR MARKER;

ACCURACY; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; EARLY CANCER; HUMAN; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PANCREATITIS; SENSITIVITY AND SPECIFICITY; BLOOD; DIFFERENTIAL DIAGNOSIS; PANCREAS TUMOR; PROTEIN MICROARRAY;

CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARRIER PROTEINS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MEMBRANE PROTEINS; MUCIN 5AC; PANCREATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855283454     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029180     Document Type: Article

References (36)

1. Maitra A, Hruban RH, (2008) Pancreatic cancer. Annu Rev Pathol 3: 157-188.
2. Kloppel G, Adsay NV, (2009) Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch Pathol Lab Med 133: 382-387.
3. Horwhat JD, Gress FG, (2004) Defining the diagnostic algorithm in pancreatic cancer. Jop 5: 289-303.
4. Goonetilleke KS, Siriwardena AK, (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33: 266-270.
5. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, et al. (1987) Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 47: 5501-5503.
6. Barton JG, Bois JP, Sarr MG, Wood CM, Qin R, et al. (2009) Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg 13: 2050-2058.
7. Lahdenne P, Pitkanen S, Rajantie J, Kuusela P, Siimes MA, et al. (1995) Tumor markers CA 125 and CA 19-9 in cord blood and during infancy: developmental changes and use in pediatric germ cell tumors. Pediatr Res 38: 797-801.
8. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V, (1983) Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 43: 5489-5492.
9. Kalthoff H, Kreiker C, Schmiegel WH, Greten H, Thiele HG, (1986) Characterization of CA 19-9 bearing mucins as physiological exocrine pancreatic secretion products. Cancer Res 46: 3605-3607.
10. Yue T, Partyka K, Maupin KA, Hurley M, Andrews P, et al. (2011) Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics.
11. Hollingsworth MA, Swanson BJ, (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4: 45-60.
12. Chen S, LaRoche T, Hamelinck D, Bergsma D, Brenner D, et al. (2007) Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods 4: 437-444.
13. Yue T, Goldstein IJ, Hollingsworth MA, Kaul K, Brand RE, et al. (2009) The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics 8: 1697-1707.
14. Haab BB, Porter A, Yue T, Li L, Scheiman J, et al. (2010) Glycosylation Variants of Mucins and CEACAMs as Candidate Biomarkers for the Diagnosis of Pancreatic Cystic Neoplasms. Annals of Surgery 251: 937-945.
15. Forrester S, Kuick R, Hung KE, Kucherlapati R, Haab BB, (2007) Low-volume, high-throughput sandwich immunoassays for profiling plasma proteins in mice: identification of early-stage systemic inflammation in a mouse model of intestinal cancer. Molecular Oncology 1: 216-225.
16. Pines JM, (2009) Trends in the rates of radiography use and important diagnoses in emergency department patients with abdominal pain. Med Care 47: 782-786.
17. Hirano K, Kawa S, Oguchi H, Kobayashi T, Yonekura H, et al. (1987) Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels. J Natl Cancer Inst 79: 1261-1268.
18. Pour PM, Tempero MM, Takasaki H, Uchida E, Takiyama Y, et al. (1988) Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Res 48: 5422-5426.
19. Schweitzer B, Roberts S, Grimwade B, Shao W, Wang M, et al. (2002) Multiplexed protein profiling on microarrays by rolling-circle amplification. Nat Biotechnol 20: 359-365.
20. Zhou H, Bouwman K, Schotanus M, Verweij C, Marrero JA, et al. (2004) Two-color, rolling-circle amplification on antibody microarrays for sensitive, multiplexed serum-protein measurements. Genome Biol 5: R28.
21. Schmidt BF, Chao J, Zhu Z, DeBiasio RL, Fisher G, (1997) Signal amplification in the detection of single-copy DNA and RNA by enzyme-catalyzed deposition (CARD) of the novel fluorescent reporter substrate Cy3.29-tyramide. J Histochem Cytochem 45: 365-373.
22. Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, et al. (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28: 595-599.
23. Jacobs CB, Peairs MJ, Venton BJ, (2010) Review: Carbon nanotube based electrochemical sensors for biomolecules. Anal Chim Acta 662: 105-127.
24. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
25. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, et al. (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63: 8614-8622.
26. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, et al. (2003) Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63: 2649-2657.
27. McEver RP, (1997) Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj J 14: 585-591.
28. Varki AP, Baum LG, Bellis SL, Cummings RD, Esko JD, et al. (2008) Working group report: the roles of glycans in hemostasis, inflammation and vascular biology. Glycobiology 18: 747-749.
29. Adsay NV, (2006) Role of MUC genes and mucins in pancreatic neoplasia. Am J Gastroenterol 101: 2330-2332.
30. Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, et al. (2007) Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 122: 418-429.
31. Napoletano C, Rughetti A, Agervig Tarp MP, Coleman J, Bennett EP, et al. (2007) Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res 67: 8358-8367.
32. Saeland E, van Vliet SJ, Backstrom M, van den Berg VC, Geijtenbeek TB, et al. (2007) The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother 56: 1225-1236.
33. Haab BB, (2010) Antibody-lectin sandwich arrays for biomarker and glycobiology studies. Expert Rev Proteomics 7: 9-11.
34. Ringel J, Lohr M, (2003) The MUC gene family: Their role in diagnosis and early detection of pancreatic cancer. Mol Cancer 2: 9.
35. Zeng Z, Hincapie M, Haab BB, Hanash S, Pitteri SJ, et al. (2009) The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. J Chromatogr A In press.
36. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD, (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100: 1432-1438.